Mirzotamab Biosimilar – Anti-CD276, B7-H3 mAb – Research Grade

Description of Mirzotamab Biosimilar - Anti-CD276, B7-H3 mAb - Research Grade

Title: Mirzotamab Biosimilar – A Promising Antibody for Targeting B7-H3 in

Cancer Therapy Introduction:

Mirzotamab Biosimilar, also known as Anti-CD276 or B7-H3 mAb, is a novel monoclonal antibody that has shown promising results in cancer therapy. This biosimilar is designed to target B7-H3, a protein that is overexpressed in various types of cancer, making it an attractive therapeutic target. In this article, we will discuss the structure, mechanism of action, and potential applications of Mirzotamab Biosimilar in cancer treatment.

Structure of Mirzotamab Biosimilar:

Mirzotamab Biosimilar is a fully human monoclonal antibody with a molecular weight of approximately 150 kDa. It consists of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chain contains a constant region (Fc) and a variable region (Fab), while the light chain has only a variable region. The variable regions of both the heavy and light chains are responsible for binding to the target protein, B7-H3.

Mechanism of Action:

B7-H3 is a cell surface protein that is overexpressed in various types of cancer, including lung, breast, and prostate cancer. It plays a crucial role in tumor growth and progression by promoting angiogenesis, suppressing immune response, and enhancing tumor cell survival. Mirzotamab Biosimilar works by binding to B7-H3 and blocking its activity, thus inhibiting tumor growth and promoting immune response against cancer cells.

Applications of Mirzotamab Biosimilar:

1. Targeted Therapy for

Cancer:

Mirzotamab Biosimilar has shown promising results in preclinical studies as a targeted therapy for various types of cancer. In a study conducted on lung cancer cell lines, Mirzotamab Biosimilar was found to significantly inhibit tumor growth and induce cell death. Similarly, in a study on breast cancer, this biosimilar showed a significant reduction in tumor size and improved survival rates. These results indicate the potential of Mirzotamab Biosimilar as a targeted therapy for cancer.

2. Combination Therapy:

Mirzotamab Biosimilar has also shown potential as a combination therapy in cancer treatment. In a study on prostate cancer, it was found that the combination of Mirzotamab Biosimilar and another targeted therapy resulted in a more significant reduction in tumor growth compared to either therapy alone. This suggests that Mirzotamab Biosimilar can be used in combination with other therapies to enhance their efficacy.

3. Immunotherapy:

B7-H3 is known to suppress immune response against cancer cells, making them resistant to conventional therapies. By blocking the activity of B7-H3, Mirzotamab Biosimilar can restore immune response and sensitize cancer cells to other treatments. This makes it a potential candidate for immunotherapy in cancer treatment.

4. Research Grade Antibody:

Apart from its therapeutic applications, Mirzotamab Biosimilar can also be used as a research grade antibody for studying the role of B7-H3 in cancer. Its high specificity and affinity for B7-H3 make it a valuable tool for investigating the function of this protein in different types of cancer.

Conclusion:

Mirzotamab Biosimilar is a promising antibody for targeting B7-H3 in cancer therapy. Its unique structure, mechanism of action, and potential applications make it a valuable addition to the arsenal of cancer treatments. Further clinical studies are needed to establish its safety and efficacy in humans, but the preclinical data is highly promising. With its potential to improve cancer treatment outcomes, Mirzotamab Biosimilar has the potential to make a significant impact in the field of oncology.

Mirzotamab Biosimilar - Anti-CD276, B7-H3 mAb binds to CD276 Recombinant Protein in indirect ELISA Assay

Immobilized CD276 Recombinant Protein (cat. No.PX-P4125) at 0.5µg/mL (100µL/well) can bind to Mirzotamab Biosimilar - Anti-CD276, B7-H3 mAb (cat. No.PX-TA1596) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450